

# Yan-Xia Shi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7016891/publications.pdf>

Version: 2024-02-01

14  
papers

359  
citations

1307594

7  
h-index

1125743

13  
g-index

19  
all docs

19  
docs citations

19  
times ranked

476  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). <i>Clinical Cancer Research</i> , 2022, 28, 637-645.	7.0	27
2	Perceived Importance of Breast Cancer Risk Factors: A Survey on 386 Physicians in China. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 379-382.	1.2	0
3	Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 860475.	2.8	5
4	Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 50.	7.4	113
5	PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer. <i>Disease Markers</i> , 2021, 2021, 1-10.	1.3	9
6	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. <i>Lancet</i> , 2021, 398, 303-313.	13.7	98
7	ANGPTL4 overexpression inhibits tumor cell adhesion and migration and predicts favorable prognosis of triple-negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 878.	2.6	21
8	The role of protein p16INK4a in non-opharyngeal head and neck squamous cell carcinoma in Southern China. <i>Oncology Letters</i> , 2018, 16, 6147-6155.	1.8	8
9	Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy. <i>Oncotarget</i> , 2017, 8, 5219-5232.	1.8	15
10	The prognostic value of Tiam1 protein expression in head and neck squamous cell carcinoma: a retrospective study. <i>Chinese Journal of Cancer</i> , 2015, 34, 614-21.	4.9	7
11	Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China. <i>Archives of Medical Science</i> , 2015, 3, 544-550.	0.9	5
12	Elevated ZNF703 Protein Expression Is an Independent Unfavorable Prognostic Factor for Survival of the Patients with Head and Neck Squamous Cell Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-8.	1.3	10
13	Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 705-714.	2.5	36
14	Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. <i>Medical Oncology</i> , 2012, 29, 39-47.	2.5	5